Indivior Pharmaceuticals (FRA:E7P) E10: €0.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
71 GF Score
Price €32.80
GF Value €20.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals E10?

Indivior Pharmaceuticals FRA:E7P -1.20% 71 E10 is €0.56 as of Jun. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 71/100 and a GF Value™ of €20.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Indivior Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.851. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.56 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Indivior Pharmaceuticals's average E10 Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-12), Indivior Pharmaceuticals's current stock price is €32.80. Indivior Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 was €0.56. Indivior Pharmaceuticals's Shiller PE Ratio of today is 58.57.

During the past 13 years, the highest Shiller PE Ratio of Indivior Pharmaceuticals was 70.90. The lowest was 11.30. And the median was 21.10.


Indivior Pharmaceuticals  (FRA:E7P) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Indivior Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=32.80/0.56
=58.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Indivior Pharmaceuticals was 70.90. The lowest was 11.30. And the median was 21.10.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Indivior Pharmaceuticals E10 Related Terms


Indivior Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals E10 Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.85 0.56 0.47

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.44 0.47 0.50 0.56

FRA:E7P vs KNSA, AMRX, HIMS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Shiller PE Ratio falls into.


FRA:E7P
71GF Score
Indivior Pharmaceuticals Inc FRA:E7P
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Indivior Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.851/333.9520*333.9520
=0.851

Current CPI (Jun. 2026) = 333.9520.

Indivior Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201609 -0.936 241.428 -1.295
201612 0.474 241.432 0.656
201703 0.514 243.801 0.704
201706 0.445 244.955 0.607
201709 0.294 246.819 0.398
201712 -0.845 246.524 -1.145
201803 0.487 249.554 0.652
201806 0.385 251.989 0.510
201809 0.514 252.439 0.680
201812 0.132 251.233 0.175
201903 0.398 254.202 0.523
201906 0.443 256.143 0.578
201909 0.272 256.759 0.354
201912 -0.360 256.974 -0.468
202003 -0.995 258.115 -1.287
202006 0.089 257.797 0.115
202009 0.042 260.280 0.054
202012 -0.082 260.474 -0.105
202103 0.420 264.877 0.530
202106 0.332 271.696 0.408
202109 0.153 274.310 0.186
202112 0.221 278.802 0.265
202203 0.254 287.504 0.295
202206 0.312 296.311 0.352
202209 0.283 296.808 0.318
202212 -1.265 296.797 -1.423
202303 0.290 301.836 0.321
202306 0.249 305.109 0.273
202309 -0.918 307.789 -0.996
202312 0.348 306.746 0.379
202403 0.414 312.332 0.443
202406 -0.669 314.175 -0.711
202409 0.144 315.301 0.153
202412 0.067 315.605 0.071
202503 0.351 319.799 0.367
202506 0.121 322.561 0.125
202509 0.281 324.800 0.289
202512 0.675 324.054 0.696
202603 0.597 330.213 0.604
202606 0.851 333.952 0.851

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.56 mean?
Indivior Pharmaceuticals (FRA:E7P) has a E10 of €0.56 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' E10 too high?
Indivior Pharmaceuticals' current E10 is €0.56. Overall, Indivior Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' E10 compare to KNSA and AMRX?
Indivior Pharmaceuticals' E10 of €0.56 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current E10 is €0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.68, compared to a current price of €32.80 — trading 58.6% above its estimated fair value. The current E10 is €0.56. Indivior Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current E10 is €0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €32.80 is trading 58.6% above its estimated GF Value™ of €20.68. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • E10: €0.56
  • GF Value™: €20.68 vs. price of €32.80 (58.6% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
71GF Score

Get the complete analysis for FRA:E7P

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.80
Price
€20.68
GF Value